IQVIA vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 77)
IQVIA logo

IQVIA

LeaderHealthcare Tech

Enterprise

World's largest CRO and healthcare data company; $15.2B FY2024 revenue; 1B+ patient records; powers pharma R&D and commercial analytics; benefits from GLP-1 and oncology pipeline boom.

AI VisibilityBeta
Overall Score
B77
Category Rank
#68 of 596
AI Consensus
69%
Trend
stable
Per Platform
ChatGPT
72
Perplexity
82
Gemini
74

About

IQVIA Holdings is the world's largest contract research organization (CRO) and leading provider of healthcare data and analytics, formed in 2016 through the $9 billion merger of IMS Health (healthcare information and technology services) and Quintiles Transnational Holdings (clinical research services), headquartered in Durham, North Carolina and trading on NYSE (IQV). The company generated approximately $15.2 billion in revenues for FY2024 under CEO Ari Bousbib, who led both legacy companies and has driven the combined entity to become an indispensable partner to pharmaceutical and biotechnology companies across the drug development lifecycle—from clinical trial design and execution through regulatory approval and commercial launch analytics.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

77
Overall Score
90
#68
Category Rank
#2
69
AI Consensus
83
stable
Trend
stable
72
ChatGPT
92
82
Perplexity
93
74
Gemini
89
82
Claude
96
72
Grok
95

Key Details

Category
Enterprise
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Integrations

Both integrate with
Only IQVIA
IQVIA is classified as company. Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.